Drug Trial Radar · NCT00330148
Randomized Clinical Trial of Three Drug Combinations for Late-Stage Gambiense Human African Trypanosomiasis
Last checked: Nov 20, 2026Latest source record: May 26, 2006 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
435
Actual
Start
Mar 2001
Primary completion
Not stated
Study completion Jun 2004
Sponsor
- Lead sponsor
- EpicentreAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Médecins Sans Frontières, France; Embassy of France in Uganda; National Sleeping Sickness Control Program, Uganda
- First posted
- May 26, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 0 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The treatment human African trypanosomiasis (HAT) in the meningoencephalitic phase relies on two molecules officially registered: melarsoprol, the most commonly used, has a poor safety profile and is becoming ineffective due to parasite resistance; and eflornithine, with better tolerance but more complicated and expensive to implement in endemic countries. nifurtimox, registered only for Chagas' disease but used off-label since the 1970's in series of cases of HAT, is at present the only other available alternative. The very limited number of compounds available, the lack of prospects for the development of new products and the emergence of resistance are arguments for the use of therapeutic combinations. This study evaluates the efficacy and safety of three drug combination therapies: melarsoprol-nifurtimox, melarsoprol-eflornithine and eflornithine-nifurtimox.
Conditions
- Trypanosomiasis, African
Interventions
melarsoprol 1.8 mg/kg/d, 10d + nifurtimox 15/20 mg/kg/d, 10dDrug
melarsoprol 1.8 mg/kg/d, 10d + eflornithine 400 mg/kg/d, 7dDrug
nifurtimox 15/20 mg/kg/d 10d + eflornithine 400 mg/kg/d 7dDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cure rate
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Omugo Sleeping Sickness Treatment Center
Omugo, Arua District, Uganda
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.